Study of a new injection for neovascular age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests a new medication, OCUL101, given as an injection into the eye, to see if it is safe and effective for people with a certain type of wet age-related macular degeneration (AMD). The trial compares OCUL101 with another standard treatment, looking at how well it works and how long it lasts over 96 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 89 years old.
- You have wet AMD that has not been treated before, with new blood vessel growth under the retina (called choroidal neovascularization), with or without geographic atrophy.
- Your vision in the study eye is between 20/40 and 20/320, measured with an eye chart.
- You have not had any prior treatment for this condition in the study eye, such as injections, laser, or surgery.
- You are able and willing to attend multiple clinic visits over about 2 years.
- If you can get pregnant, you must agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This trial tests a new treatment called IVB103 for people with wet age-related macular degeneration (AMD). It aims to see if the injection is safe and effective for those who have already had anti-VEGF therapy. You may qualify if you have active disease and have had at least two prior anti-VEGF treatments.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This trial tests a new eye injection called GB10 for people with wet AMD, a condition that causes rapid vision loss. The goal is to see if it is safe and works to improve or stabilize vision.
This study looks at whether certain proteins or molecules in the jelly-like fluid inside the eye can predict why some people with wet age-related macular degeneration do not respond well to standard anti-VEGF injections. By studying these signals, researchers hope to improve future treatment and better tailor care to individual patients.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
Hear when a new Adults With Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.